Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q4 EPS of $0.86, $0.16 better than the analyst estimate of $0.70. Revenue for the quarter came in at $563.3 million versus the consensus estimate of $518.36 million.

For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.

Earnings